Reviva Pharmaceuticals Holdings, Inc. (RVPH) Misses Q2 EPS by 27c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Anthropic's Claude AI identifies novel enzyme system in DNA search
- Wall Street ends down as oil prices, Treasury yields rise
- AppLovin (APP) on watch amid 3% drop premarket as boutique comments circulate
- Plug Power COO resigns to join another company
- Xtend AI Robotics wins Phase III of USSOCOM lethal drone program
Reviva Reports Second Quarter 2023 Financial Results and Recent Business Highlights
August 14, 2023 4:01 PM EDT- Topline data for global pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia expected in October 2023 -
- Completion of 1-year open-label extension clinical trial for brilaroxazine in schizophrenia expected in Q3 2024 -
CUPERTINO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (Reviva or the Company), a late-stage pharmaceutical company developing new therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometablolic diseases, today reported financial results for the second quarter ended June 30, 2023 and summarized recent... More
